Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 26;7(1):92–105. doi: 10.1182/bloodadvances.2022008121

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 6. — Validation of the antiproliferative activity of UBX-382 in diverse cell lines derived from hematological malignancies. (A) Inhibitory effects of ibrutinib (yellow circle), ARQ-531 (purple diamond), Thalidomide (hunter green triangle), Lenalidomide (sky blue inverted triangle), and UBX-382 (red square) on cell proliferation in the examined cell lines at the indicated increasing doses were monitored for 5 days by performing Cell Titer-Glo 2.0 Assay. Germinal center B-cell (GCB)–like DLBCL cell line: Su-DHL10; multiple myeloma cell line: U266; follicular lymphoma (FL) cell line: DOHH2; MCL cell line: MINO; chronic myeloid leukemia (CML) cell line: K562; and acute myeloid leukemia (AML) cell line: MOLM13. Experiments were performed in duplicates. All data are expressed as the mean ± SEM. (B) Immunoblotting analysis of BTK degradation and CRBN neosubstrates after treatment with UBX-382 and thalidomide. Hematological cell lines (U2932, TMD-8, DOHH2, MINO, K562, and WSU-WM) were treated with 100 nM thalidomide and UBX-382 for 24 hours and 72 hours. Immunoblotting was performed to verify the levels of BTK, Ikaros, Helios, Aiolos, GSPT1, and CK1-α using specific antibodies. (C) CRBN neosubstrate protein levels were measured by immunoblotting and values of the remaining substrates, Ikaros, Aiolos, GSPT1, and CK1-α, were normalized using GAPDH intensity value as a loading control. WM, Waldenström macroglobulinemia.

Figure 6. — Validation of the antiproliferative activity of UBX-382 in diverse cell lines derived from hematological malignancies. (A) Inhibitory effects of ibrutinib (yellow circle), ARQ-531 (purple diamond), Thalidomide (hunter green triangle), Lenalidomide (sky blue inverted triangle), and UBX-382 (red square) on cell proliferation in the examined cell lines at the indicated increasing doses were monitored for 5 days by performing Cell Titer-Glo 2.0 Assay. Germinal center B-cell (GCB)–like DLBCL cell line: Su-DHL10; multiple myeloma cell line: U266; follicular lymphoma (FL) cell line: DOHH2; MCL cell line: MINO; chronic myeloid leukemia (CML) cell line: K562; and acute myeloid leukemia (AML) cell line: MOLM13. Experiments were performed in duplicates. All data are expressed as the mean ± SEM. (B) Immunoblotting analysis of BTK degradation and CRBN neosubstrates after treatment with UBX-382 and thalidomide. Hematological cell lines (U2932, TMD-8, DOHH2, MINO, K562, and WSU-WM) were treated with 100 nM thalidomide and UBX-382 for 24 hours and 72 hours. Immunoblotting was performed to verify the levels of BTK, Ikaros, Helios, Aiolos, GSPT1, and CK1-α using specific antibodies. (C) CRBN neosubstrate protein levels were measured by immunoblotting and values of the remaining substrates, Ikaros, Aiolos, GSPT1, and CK1-α, were normalized using GAPDH intensity value as a loading control. WM, Waldenström macroglobulinemia.